MedTrace Logo

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

NCT03686709 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-09-27

No results posted yet for this study

Summary

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Post therapy PET/CT Imaging

whole-body PET/CT following Y90 radioembolization

Sponsors & Collaborators

  • Biocompatibles UK Ltd

    collaborator INDUSTRY

  • University of Tennessee

    lead OTHER

Principal Investigators

  • Dustin Osborne, PhD · University of Tennessee

  • Christopher Stephens, MD · University of Tennessee

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-19
Primary Completion
2019-06-18
Completion
2019-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03686709 on ClinicalTrials.gov